p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.
about
The Role of Autophagy in Hepatocellular CarcinomaCancer-associated fibroblasts in digestive tumorsCytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significanceFibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.miR-21 in ischemia/reperfusion injury: a double-edged sword?Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasisIL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms.Prognostic and clinicopathological significance of Gankyrin overexpression in cancers: evidence from a meta-analysisUp-regulated oncoprotein P28GANK correlates with proliferation and poor prognosis of human glioma.A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expressionGankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway.A Targetable Molecular Chaperone Hsp27 Confers Aggressiveness in Hepatocellular CarcinomaAltered expression of norepinephrine transporter and norepinephrine in human placenta cause pre-eclampsia through regulated trophoblast invasion.PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expressionEvidence for and against epithelial-to-mesenchymal transition in the liver.MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma.Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.The transcription levels and prognostic values of seven proteasome alpha subunits in human cancersIL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.New phosphatidylinositol 3-kinase inhibitors for cancer.PI3K: a potential therapeutic target for cancer.Hypoxia and hypoxia inducible factors: diverse roles in liver diseases.Biomarkers for predicting future metastasis of human gastrointestinal tumors.The impact of hypoxia in hepatocellular carcinoma metastasis.The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.Twist in hepatocellular carcinoma: pathophysiology and therapeutics.The role of TWIST1 in epithelial-mesenchymal transition and cancers.Gankyrin regulates cell signaling network.BAG3 regulates epithelial-mesenchymal transition and angiogenesis in human hepatocellular carcinoma.SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition.Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability.Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug.αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma.Gankyrin as a potential therapeutic target for cancer.Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.
P2860
Q26777419-1C91124F-7796-49E8-8457-A546E1E8A3E1Q27022816-9855DCDA-D460-4895-983D-2D1A7C551DBAQ33802655-D7AF17FF-7060-424D-821D-B929500536F6Q33851157-1A7F6CD7-E31F-48B4-8561-1A2771F44059Q34309876-12A157E7-E881-4B1E-9E53-AF58277E3A84Q34619226-9CCECDA8-F513-472A-B249-733A90ED1DEBQ34790075-C5826DF0-4B9A-40E5-8421-F6C4D7CD62ABQ35153915-A3369E0E-A0BA-4348-AD3F-181DBFCE1C69Q35847817-8C07BFCE-AC6F-47BB-ACBB-7B091E1946B3Q35972785-06DA1CFF-2ADA-4920-A469-FDC6E43A4C71Q35997896-BE9B522D-BC64-4418-AFD2-3FAE20DD7B07Q36235734-BD09C650-9496-495E-90CA-9FAB6CA2F70AQ36251372-E933CC3F-1A34-463D-92E2-4564BE3E279DQ36346927-B0782A3F-7912-44E5-A11F-D025A2D70D31Q36644350-E5820980-8D26-4F9A-9A8A-6964BAD38FE3Q36778205-0890C30F-7687-4318-A32C-B64BF606D815Q37141742-48FC322D-71F5-49C5-A0EA-281F79B38C68Q37440129-85114D8A-13BD-4567-A9BB-5CEB5985C3B1Q37520584-01F9B0A3-EF7E-425E-9048-8DB547CA7612Q37697139-6CC8E86F-2C2C-4EE0-AC33-B4A7EB1EC2ADQ37706211-EB096BD5-D3E4-40EB-9F68-E56F2126479FQ37709089-270B0B5C-D9E0-42C6-85A3-1C09311C8D70Q37851994-3B697B09-4C5A-46D2-8462-39ADC3D1F16AQ37936950-28F39893-A8A6-4748-B319-C78C3A97D9A1Q37961603-1F20F115-D358-4753-B0ED-2EF96B956721Q38078237-75C57DC3-07A5-4E5A-B5A5-134335AE46F5Q38162804-ABB131E2-92A2-47D7-8F50-0B729E411533Q38178032-ED071680-9530-43EF-A7E4-267ED6D6D4CBQ38504290-93C4E329-682A-46CF-A003-DFB42058CF18Q38646345-D8AE8525-0D62-4FB6-9D11-B3DC3EAD0149Q38714564-1BE9F3C9-9E2D-405D-9EDC-C7004F654CDAQ39040786-DBFD8841-EE55-463F-A852-2560537BB689Q39169788-372ADF50-8246-4098-B37D-9D0BEB8DC3A0Q39171575-21212787-66D1-4B33-AC48-B2CA3E63188DQ39179303-0452520D-F6AE-4740-861C-ECAC0A681BFFQ39190601-FBD49B92-E9BC-4F65-A4A1-3661828D9270Q39211222-6FA3EBA2-F407-4114-A35A-F160CA206E50Q39230141-17CBA2F3-C756-47B1-BD78-8710A4C1230AQ39319386-E8AB230B-680A-4A89-B09A-0D4458FC75D6Q39511329-2F43B770-F117-422C-9823-71EB659560E4
P2860
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@en
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@nl
type
label
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@en
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@nl
prefLabel
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@en
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@nl
P2093
P2860
P356
P1433
P1476
p28GANK overexpression acceler ...... -inducible factor-1α pathways.
@en
P2093
Gen-Sheng Feng
Guang-Wen Cao
Hong-Yang Wang
Meng-Chao Wu
P2860
P304
P356
10.1002/HEP.24015
P407
P577
2010-12-10T00:00:00Z